← Back to Home

Targeting KRAS G12D: VS-7375 Shows Tumor Shrinkage in Early Pancreatic Cancer Trial

Among 22 previously treated patients with metastatic pancreatic cancer, 9 had confirmed tumor responses. These preliminary data offer clues for a precision-targeted strategy, but larger controlled trials are still needed to determine whether it can extend survival.

By SURL BioNews

For patients with previously treated metastatic pancreatic cancer, whether a new drug can shrink tumors is an important clue in identifying the next treatment option. Verastem announced early clinical results for its oral KRAS G12D inhibitor VS-7375, reporting antitumor activity in patients with this mutation, and plans to initiate a Phase 3 trial by the end of 2026. However, the current evidence comes from a small study without a control group and cannot establish that the new drug is superior to existing therapies.

The results come from the Phase 1/2 TARGET-D 101 trial. Twenty-two previously treated patients with metastatic pancreatic ductal adenocarcinoma received 900 mg of VS-7375 daily, with a median follow-up of 6.4 months. Nine had confirmed objective responses, for a response rate of approximately 41%; 4 of the 8 patients receiving second-line treatment responded, as did 5 of the 14 receiving third- or fourth-line treatment. The study also observed two complete responses, but one still awaits confirmation through follow-up assessments, so both cannot be considered confirmed results.

The development strategy for VS-7375 is to select patients based on their tumors’ KRAS G12D mutation, rather than treating all patients with pancreatic cancer as a single group. This also defines the scope of the data: the responses observed so far come from patients with a specific mutation who met the trial’s eligibility criteria and cannot be directly generalized to pancreatic cancer populations with other molecular profiles or different physical conditions.

Beyond imaging, blood tests also showed changes. According to Targeted Oncology, among 17 patients with pancreatic cancer whose CA19-9 levels were elevated before treatment, 15 had declines of more than half; another 12 patients initially had detectable KRAS G12D circulating tumor DNA in their blood, and levels became undetectable in 7 of them on subsequent testing. These results provide another indication of drug activity, but a decline in a marker or an undetectable result does not mean the cancer has been eradicated and cannot substitute for survival outcomes.

The safety data cover 48 patients across different cancer types who received 900 mg daily as monotherapy, rather than only the pancreatic cancer population described above. Grade 3 treatment-related adverse events occurred in 10%, and 2% discontinued treatment because of adverse events; common treatment-related symptoms included low-grade nausea, vomiting, and diarrhea. This preliminary record helps inform subsequent dose selection and combination therapy design, but the sample size and follow-up duration still limit assessments of rare or long-term risks.

The efficacy figures must be interpreted with the same perspective. The 50% response rate in second-line treatment comes from just 8 patients, so a few cases could substantially change the proportion; the study had no concurrent control group and cannot rule out the influence of factors such as patient selection. Reports by both OncLive and Targeted Oncology cited company-released data, and agreement between the two reports does not mean that another independent study has reproduced the results. How long responses last, whether quality of life improves, and whether survival is extended remain key questions for the next stage.

Verastem’s planned Phase 3 TARGET-D 301 trial will advance the research into first-line metastatic pancreatic cancer, separately evaluating VS-7375 combined with anti-EGFR therapy and VS-7375 combined with gemcitabine and albumin-bound paclitaxel, and comparing them with investigator-selected chemotherapy. Progression-free survival and objective response rate will be dual primary endpoints, with overall survival as a secondary endpoint. Because the new trial uses combination therapy in a different line of treatment, the existing monotherapy results provide a basis for advancing the research, while actual clinical benefit still requires comparative validation.

References

  1. OncLive
  2. Targeted Oncology